Clinical Overview
Triazolam is a short-acting benzodiazepine indicated for the short-term treatment of insomnia. It has one of the shortest half-lives among benzodiazepines (1.5-5.5 hours), making it suitable for sleep initiation with minimal next-day sedation, but it also carries higher risks of rebound insomnia and anterograde amnesia compared to longer-acting alternatives.
Primary Clinical Applications
Triazolam is indicated for the short-term treatment of insomnia characterized by difficulty falling asleep. Its ultra-short duration of action makes it suitable for patients who need rapid sleep onset without next-day impairment, but it is not effective for sleep maintenance problems.
Mechanism and Clinical Benefits
Triazolam enhances GABA activity at benzodiazepine receptors, providing rapid sleep induction. Its very short half-life allows for quick elimination, reducing next-day sedation, but this also increases the risk of rebound anxiety and insomnia between doses or upon discontinuation.
Clinical Considerations
Due to its potency and short half-life, triazolam has a higher risk of causing anterograde amnesia, rebound insomnia, and withdrawal symptoms compared to other benzodiazepines. It should be used only for short periods (7-10 days) and requires careful dose titration. The medication has significant drug interactions due to CYP3A4 metabolism.
Prescribing Information
Dosing & Administration
Insomnia – Adults:
- Initial: 0.125-0.25 mg immediately before bedtime
- Range: 0.125-0.5 mg once daily
- Maximum: 0.5 mg once daily
Elderly or Debilitated:
- Initial and maximum: 0.125 mg immediately before bedtime
- May increase to 0.25 mg if needed and tolerated
Administration:
- Take immediately before bedtime
- Ensure 7-8 hours available for sleep
- Do not take with grapefruit juice
- Limit treatment duration to 7-10 days
Indications
- Short-term treatment of insomnia (7-10 days)
- Difficulty with sleep initiation
Contraindications
- Hypersensitivity to benzodiazepines
- Concurrent use with strong CYP3A4 inhibitors (ketoconazole, itraconazole)
- Pregnancy (particularly first trimester)
- Sleep apnea syndrome
Warnings & Precautions
- Boxed Warning: Risk of abuse, misuse, dependence; respiratory depression with opioids
- Anterograde amnesia: Higher risk than with other benzodiazepines
- Complex sleep behaviors: Sleep-driving, sleep-eating reported
- Rebound insomnia: Common due to short half-life
- Withdrawal syndrome: Can occur even after short-term use
- Next-day impairment: Despite short half-life, impairment possible
Drug Interactions
- Strong CYP3A4 inhibitors: Contraindicated – significantly increase triazolam levels
- Moderate CYP3A4 inhibitors: Reduce triazolam dose
- Grapefruit juice: Increases triazolam levels
- CNS depressants: Enhanced sedation and respiratory depression
- Opioids: Increased risk of respiratory depression and death
Adverse Reactions
Common (>5%):
- Drowsiness, headache, dizziness, nervousness
- Light-headedness, coordination disorders
Serious:
- Anterograde amnesia, complex sleep behaviors
- Respiratory depression, severe withdrawal
- Paradoxical reactions (agitation, hostility)
Special Populations
- Elderly: Maximum 0.125-0.25 mg due to increased sensitivity
- CYP3A4 interactions: Many clinically significant interactions
- Pregnancy: Category X – contraindicated in pregnancy
- Short-term use only: 7-10 days maximum to minimize dependence risk
Medical Disclaimer: This information is for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare professionals before making any treatment decisions. Individual patient circumstances may vary significantly.
